Here are the 10-K annual reports from Lunai Bioworks Inc. (RENB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RENB filings page.
Lunai Bioworks, Inc. is a pre-clinical biotechnology company that develops AI-driven multi-omic diagnostic and therapeutic tools and completed several strategic acquisitions to expand its AI and diagnostics capabilities.
The company reported a cash balance of $92,700, an accumulated deficit of $510,462,570 and a working capital deficit of $28,109,502, and discloses substantial doubt about its ability to continue as a going concern for one year after issuance of the financial statements. Lunai completed acquisitions (including Renovaro Cube and GEDi Cube) and recorded related contingent consideration and share issuances. At June 30, 2025 the company had 177,392,907 shares outstanding (up from 158,452,644 the prior year) and significant stock-based compensation expense of $3,313,291 for the year. The company also had multiple convertible and promissory notes outstanding and disclosed a subsequent debt-for-equity exchange that resulted in issuance of 53.6 million shares upon conversion of $16.1 million of convertible notes.